Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504044-34-00

Acronym

54179060CLL2032

Enrollment

213

Registered

2023-11-29

Start date

2024-04-17

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untreated Chronic Lymphocytic Leukemia

Brief summary

Best ORR by investigator assessment

Interventions

DRUGJNJ-54179060

DRUGVenclyxto 50 mg film-coated tablets

DRUGVenclyxto 10 mg film-coated tablets

DRUGIMBRUVICA 140 mg hard capsules

DRUGVenclyxto 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Best ORR by investigator assessment	—

Countries

Czechia, France, Hungary, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026